OBJECTIVE: To (1) evaluate the feasibility of touch screen depression screening in cancer patients using the Patient Health Questionnaire-9 (PHQ-9), (2) evaluate the construct validity of the PHQ-9 using the touch screen modality, and (3) examine the prevalence and severity of depression using this screening modality. METHODS: The PHQ-9 was placed in a web-based survey within a study of the clinical impact of computerized symptom and quality of life screening. Patients in medical oncology, radiation oncology, and hematopoietic stem cell transplantation (HSCT) clinics used the program on a touch screen computer in waiting rooms prior to therapy (T1) and during therapy (T2). Responses of depressed mood or anhedonia (PHQ-2 cardinal depression symptoms) triggered additional items. PHQ-9 scores were provided to the oncology team in real time. RESULTS: Among 342 patients enrolled, 33 (9.6%) at T1 and 69 (20.2%) at T2 triggered the full PHQ-9 by endorsing at least one cardinal symptom. Feasibility was high, with at least 97% completing the PHQ-2 and at least 96% completing the PHQ-9 when triggered and a mean completion time of about 2 min. The PHQ-9 had good construct validity. Medical oncology patients had the highest percent of positive screens (12.9%) at T1, while HSCT patients had the highest percent (30.5%) at T2. Using this method, 21 (6.1%) at T1 and 54 (15.8%) at T2 of the total sample had moderate to severe depression. CONCLUSIONS: The PHQ-9 administered on a touch screen computer is feasible and provides valid depression data in a diverse cancer population. (c) 2008 John Wiley & Sons, Ltd.
OBJECTIVE: To (1) evaluate the feasibility of touch screen depression screening in cancerpatients using the Patient Health Questionnaire-9 (PHQ-9), (2) evaluate the construct validity of the PHQ-9 using the touch screen modality, and (3) examine the prevalence and severity of depression using this screening modality. METHODS: The PHQ-9 was placed in a web-based survey within a study of the clinical impact of computerized symptom and quality of life screening. Patients in medical oncology, radiation oncology, and hematopoietic stem cell transplantation (HSCT) clinics used the program on a touch screen computer in waiting rooms prior to therapy (T1) and during therapy (T2). Responses of depressed mood or anhedonia (PHQ-2 cardinal depression symptoms) triggered additional items. PHQ-9 scores were provided to the oncology team in real time. RESULTS: Among 342 patients enrolled, 33 (9.6%) at T1 and 69 (20.2%) at T2 triggered the full PHQ-9 by endorsing at least one cardinal symptom. Feasibility was high, with at least 97% completing the PHQ-2 and at least 96% completing the PHQ-9 when triggered and a mean completion time of about 2 min. The PHQ-9 had good construct validity. Medical oncology patients had the highest percent of positive screens (12.9%) at T1, while HSCT patients had the highest percent (30.5%) at T2. Using this method, 21 (6.1%) at T1 and 54 (15.8%) at T2 of the total sample had moderate to severe depression. CONCLUSIONS: The PHQ-9 administered on a touch screen computer is feasible and provides valid depression data in a diverse cancer population. (c) 2008 John Wiley & Sons, Ltd.
Authors: Michael P Pignone; Bradley N Gaynes; Jerry L Rushton; Catherine Mills Burchell; C Tracy Orleans; Cynthia D Mulrow; Kathleen N Lohr Journal: Ann Intern Med Date: 2002-05-21 Impact factor: 25.391
Authors: Donna L Berry; Brent A Blumenstein; Barbara Halpenny; Seth Wolpin; Jesse R Fann; Mary Austin-Seymour; Nigel Bush; Bryant T Karras; William B Lober; Ruth McCorkle Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: Timothy W Bickmore; Suzanne E Mitchell; Brian W Jack; Michael K Paasche-Orlow; Laura M Pfeifer; Julie Odonnell Journal: Interact Comput Date: 2010-07-01 Impact factor: 1.174
Authors: Cornelia M Ruland; Harald H Holte; Jo Røislien; Cathy Heaven; Glenys A Hamilton; Jørn Kristiansen; Heidi Sandbaek; Stein O Kvaløy; Line Hasund; Misoo C Ellison Journal: J Am Med Inform Assoc Date: 2010 Jul-Aug Impact factor: 4.497
Authors: William F Pirl; Joseph A Greer; Lara Traeger; Vicki Jackson; Inga T Lennes; Emily R Gallagher; Pedro Perez-Cruz; Rebecca S Heist; Jennifer S Temel Journal: J Clin Oncol Date: 2012-03-19 Impact factor: 44.544
Authors: Jessica R Gorman; H Irene Su; John P Pierce; Samantha C Roberts; Sally A Dominick; Vanessa L Malcarne Journal: J Cancer Surviv Date: 2013-12-19 Impact factor: 4.442
Authors: J Michael Randall; Rochelle Voth; Erin Burnett; Lyudmila Bazhenova; Wayne A Bardwell Journal: Support Care Cancer Date: 2013-01-17 Impact factor: 3.603